Lupus Research Alliance

Jeffrey Rathmell, PhD, left, and Kelsey Voss, PhD, led a multidisciplinary team that identified iron metabolism in T cells as a potential target for treating lupus.
January 13, 2023

Study identifies potential new approach for treating lupus

A Vanderbilt study found that targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus — the most common form of the chronic autoimmune disease lupus.

By Leigh MacMillan
January 27, 2022

Impaired neutrophils in autoimmunity

Vanderbilt researchers help answer the question of why patients with autoimmune diseases like lupus are more susceptible to bacterial infections: their neutrophils have impaired antibacterial activity.

By Leigh MacMillan
Ayaka Sugiura and Jeff Rathmell, PhD, are studying a metabolic enzyme involved in T cell function that may offer a new target for anti-inflammatory therapeutics.
November 11, 2021

CRISPR screen identifies new anti-inflammatory drug target

A novel CRISPR screen developed by Vanderbilt researchers identified a promising new target for anti-inflammatory therapeutics.

By Leigh MacMillan
July 23, 2020

Kawai receives award to accelerate lupus research

Vivian Kawai, MD, MPH, research assistant professor of Medicine, has received an LRA-BMS Accelerator Award from the Lupus Research Alliance and sponsoring partner Bristol Myers Squibb.

By Leigh MacMillan
October 31, 2019

Rathmell lands award from Lupus Research Alliance

Jeffrey Rathmell, PhD, is a 2019 recipient of the Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity.

By Tom Wilemon